CJC-1295

CJC-1295 (without DAC) is the common name for Modified GRF 1-29, a 29-amino-acid analog of endogenous growth hormone releasing hormone (GHRH). It is a truncated and stabilized version of the natural GHRH (44 amino acids), retaining the biologically active N-terminal sequence. The "without DAC" designation is critical, it distinguishes this compound from the DAC (Drug Affinity Complex) version, which has a dramatically different half-life and pharmacodynamic profile.

CJC-1295 works by binding to GHRH receptors on somatotroph cells in the anterior pituitary gland, directly stimulating the synthesis and pulsatile release of growth hormone. Unlike exogenous GH injection, which suppresses the hypothalamic-pituitary axis, CJC-1295 amplifies the body's natural GH pulses. This pulsatile pattern more closely mimics endogenous GH secretion and is believed to carry a lower risk of desensitization and side effects than continuous GH elevation.

The without-DAC form has a half-life of approximately 30 minutes, similar to natural GHRH, and clears rapidly, which is essential to preserving the pulsatile mechanism. When combined with a GHRP like ipamorelin, the two peptides produce a synergistic GH pulse that significantly exceeds what either agent achieves alone. CJC-1295 extends the GHRH signal while ipamorelin simultaneously stimulates GH release from the pituitary via the ghrelin receptor, two complementary pathways firing in concert.

A standard 2 mg vial reconstituted with 2 mL of bacteriostatic water gives 1 mg/mL (1,000 mcg/mL). At the typical 100 mcg dose, you draw 0.1 mL, 10 units on a U-100 insulin syringe. Inject subcutaneously in the abdomen 30–60 minutes before sleep in a fully fasted state. Even a small carbohydrate intake raises insulin, which triggers somatostatin release and blocks the GH pulse. Timing and fasting are as important as dosing.

CJC-1295 without DAC is not FDA-approved and is sold exclusively for research purposes. Its use is supported by analogy with well-studied GHRH analogs and extensive mechanistic literature on GHRH receptor pharmacology. The ipamorelin/CJC-1295 combination has a long track record in physician-supervised anti-aging and longevity medicine. All non-physician use is considered research.